HLA-A and cancer: To explore the potential of the PRAME-specific ImmTAC® to redirect T cells in cancer cells presenting a small number of PRAME-pHLA complexes, cell lines with varying levels of PRAME or HLA-A were probed with fluorescence-labeled PRAME-targeting ImmTAC®.